Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
Tempus announced a collaboration with Flatiron Health to integrate its genomic testing capabilities into Flatiron's OncoEMR® platform through Molecular Profiling Integration (MPI). This integration will provide 4,200 providers across 800 community-based cancer care locations with direct access to Tempus' suite of testing options within their workflow. The system enables electronic ordering, tracking, and result delivery through a unified ordering system, reducing administrative burden. The integration includes access to various Tempus tests including xT, xR, xF/xF+, xG/xG+ Ambry, and xM/xM, along with AI-enabled algorithmic add-on tests.
Tempus ha annunciato una collaborazione con Flatiron Health per integrare le sue capacità di test genomici nella piattaforma OncoEMR® di Flatiron attraverso l'Integrazione del Profilo Molecolare (MPI). Questa integrazione fornirà a 4.200 fornitori presenti in 800 strutture di assistenza oncologica comunitaria un accesso diretto alla suite di opzioni di test di Tempus all'interno del loro flusso di lavoro. Il sistema consente l'ordinazione elettronica, il tracciamento e la consegna dei risultati attraverso un sistema di ordinazione unificato, riducendo il carico amministrativo. L'integrazione include l'accesso a vari test Tempus, tra cui xT, xR, xF/xF+, xG/xG+ Ambry e xM/xM, insieme a test addizionali abilitati da algoritmi AI.
Tempus anunció una colaboración con Flatiron Health para integrar sus capacidades de pruebas genómicas en la plataforma OncoEMR® de Flatiron a través de la Integración de Perfil Molecular (MPI). Esta integración proporcionará a 4,200 proveedores en 800 ubicaciones de atención oncológica comunitaria acceso directo a la gama de opciones de pruebas de Tempus dentro de su flujo de trabajo. El sistema permite la ordenación electrónica, el seguimiento y la entrega de resultados a través de un sistema de pedidos unificado, reduciendo la carga administrativa. La integración incluye acceso a varias pruebas de Tempus, incluyendo xT, xR, xF/xF+, xG/xG+ Ambry, y xM/xM, junto con pruebas adicionales habilitadas por algoritmos de inteligencia artificial.
템퍼스는 플랫아이언 헬스와 협력하여 유전자 검사 기능을 플랫아이언의 OncoEMR® 플랫폼에 통합하는 협업을 발표했습니다. 이 통합을 통해 4,200명의 의료 제공자가 800개의 지역 기반 암 치료 장소에서 템퍼스의 다양한 검사 옵션에 직접 접근할 수 있게 됩니다. 이 시스템은 전자 주문, 추적 및 결과 전달을 통합된 주문 시스템을 통해 가능하게 하여 행정적 부담을 줄입니다. 통합에는 xT, xR, xF/xF+, xG/xG+ Ambry, xM/xM 및 AI 기반 알고리즘 보조 테스트를 포함한 다양한 템퍼스 테스트에 대한 접근이 포함됩니다.
Tempus a annoncé une collaboration avec Flatiron Health pour intégrer ses capacités de tests géniques dans la plateforme OncoEMR® de Flatiron via l'Intégration du Profil Moléculaire (MPI). Cette intégration fournira à 4 200 prestataires dans 800 sites de soins oncologiques communautaires un accès direct à la suite d'options de tests de Tempus au sein de leur flux de travail. Le système permet les commandes électroniques, le suivi et la livraison des résultats via un système de commande unifié, réduisant ainsi la charge administrative. L'intégration inclut l'accès à divers tests Tempus, y compris xT, xR, xF/xF+, xG/xG+ Ambry et xM/xM, ainsi que des tests supplémentaires activés par des algorithmes d'IA.
Tempus hat eine Zusammenarbeit mit Flatiron Health bekannt gegeben, um seine genomischen Testfähigkeiten in die OncoEMR®-Plattform von Flatiron durch die Molekulare Profilintegration (MPI) zu integrieren. Diese Integration wird 4.200 Anbietern in 800 kommunalen Onkologieeinrichtungen direkten Zugang zu Tempus’ Testsuite innerhalb ihres Workflows bieten. Das System ermöglicht elektronische Bestellungen, Nachverfolgung und Ergebnislieferung über ein einheitliches Bestellsystem, was die administrative Belastung verringert. Die Integration umfasst den Zugang zu verschiedenen Tempus-Tests, darunter xT, xR, xF/xF+, xG/xG+ Ambry und xM/xM sowie KI-gestützte algorithmische Zusatztests.
- Integration with Flatiron's OncoEMR platform expands access to 4,200 providers across 800 cancer care locations
- Streamlined workflow integration reduces administrative burden and improves operational efficiency
- Enhanced market reach through direct integration with major oncology EMR platform
- None.
Insights
This strategic integration marks a significant operational advancement in oncology care delivery. The partnership connects 4,200 providers across 800 cancer care locations with Tempus's advanced molecular testing suite through Flatiron's OncoEMR platform. The integration's value proposition centers on workflow optimization and enhanced clinical decision support.
The unified ordering system and seamless results integration directly address key operational inefficiencies in genomic testing workflows. This streamlined process should accelerate adoption of precision medicine approaches and potentially increase Tempus's test volumes across Flatiron's extensive network. The integration of AI-enabled algorithmic tests also positions Tempus to capture growing demand for advanced diagnostic tools.
From a market perspective, this collaboration strengthens Tempus's competitive position in the molecular diagnostics space by expanding its reach into community oncology practices - a important growth segment. The partnership with Flatiron, owned by Roche, adds credibility and could lead to further strategic opportunities.
Flatiron’s MPI—a two-way integration between laboratories and OncoEMR—will allow the 4,200 providers at more than 800 community-based cancer care locations across the
“This collaboration represents a significant step forward in the integration of Tempus’ molecular profiling capabilities into everyday oncology practice,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “By leveraging Flatiron’s Molecular Profiling Integration within OncoEMR, we are enabling oncologists to access our comprehensive genomic tests with greater efficiency and precision, ultimately enhancing patient care and outcomes.”
“Integrating Tempus' suite of testing options into OncoEMR marks a step forward in personalizing cancer care, enabling more precise diagnoses and tailored treatments for every person with cancer,” said Stephen Speicher, MD, Senior Medical Director, Head of Clinical Oncology and Safety at Flatiron. “This collaboration ensures oncologists across the Flatiron network have convenient access to the information needed to practice precision medicine, improve patient outcomes, and spend more meaningful time with their patients, ultimately enhancing the care experience for both providers and those they serve.”
A key feature of this integration includes unified ordering in which a single order form will be deployed across all MPI-participating practices, streamlining the process and ensuring consistency. Also, this integration will give providers comprehensive access to Tempus tests, including xT, xR, xF/xF+, xG/xG+ Ambry, xM/xM (NeXT Personal® Dx), as well as several AI-enabled, algorithmic, add-on tests.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ interoperability initiatives, integrations with electronic health record platforms, and efforts to reduce administrative burden associated with test ordering and results. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112753574/en/
Tempus Communications
Erin Carron
media@tempus.com
Flatiron Health
Nina Toor
press@flatiron.com
Source: Tempus AI, Inc.
FAQ
What is the new integration announced between Tempus (TEM) and Flatiron Health?
How many healthcare providers will have access to Tempus (TEM) testing through the Flatiron integration?
What Tempus (TEM) tests will be available through the Flatiron OncoEMR integration?
